Johnson; Lorin K.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Johnson; Lorin K..The latest application filed is for "use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders".

Company Profile

0.9.12

Johnson; Lorin K. - Los Altos Hills CA
Johnson; Lorin K. - Palo Alto CA US
Johnson; Lorin K. - Pleasanton CA
Johnson; Lorin K. - Castro Valley CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use Of Methylnaltrexone And Rifaximin For Treatment Of Increased Gut Permeability Or Associated Disorders App 20220175764 - Johnson; Lorin K. ; et al.	2022-06-09
Use Of Methylnaltrexone To Attenuate Tumor Progression App 20210121456 - Moss; Jonathan ; et al.	2021-04-29
Use Of Methylnaltrexone To Attenuate Tumor Progression App 20200163958 - Moss; Jonathan ; et al.	2020-05-28
Use Of Methylnaltrexone To Attenuate Tumor Progression App 20170202832 - Moss; Jonathan ; et al.	2017-07-20
Balsalazide Formulations And Manufacture And Use Thereof App 20160279153 - Lockhart; Joseph ; et al.	2016-09-29
Methods For Treating Bowel Diseases App 20160000765 - Forbes; William ; et al.	2016-01-07
Formulations And Uses Of 2-hydroxy-5-phenylazobenzoic Acid Derivatives For The Treatment Of Males App 20150132381 - Forbes; William ; et al.	2015-05-14
Formulations And Uses Of 2-hydroxy-5-phenylazobenzoic Acid Derivatives For The Treatment Of Males App 20130295178 - Forbes; William ; et al.	2013-11-07
Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives App 20070167416 - Johnson; Lorin K.	2007-07-19
Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents Grant 5,905,073 - Johnson , et al. May 18, 1	1999-05-18
Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents Grant 5,498,608 - Johnson , et al. March 12, 1	1996-03-12
Linear analogs of atrial natriuretic peptides Grant 5,047,397 - Scarborough , et al. September 10, 1	1991-09-10
Synovial phospholipases Grant 5,019,508 - Johnson , et al. May 28, 1	1991-05-28
Cyclic analogs of atrial natriuretic peptides Grant 4,935,492 - Lewicki , et al. * June 19, 1	1990-06-19
Analogs of atrial natriuretic peptides Grant 4,804,650 - Lewicki , et al. February 14, 1	1989-02-14
Novel atrial natriuretic/vasodilator polypeptides Grant 4,764,504 - Johnson , et al. August 16, 1	1988-08-16
Synthetic analogs of atrial natriuretic peptides Grant 4,757,048 - Lewicki , et al. July 12, 1	1988-07-12
Novel polypeptide diuretic/vasodilators Grant 4,618,600 - Johnson , et al. October 21, 1	1986-10-21

Company Registrations

SEC

0001053878

JOHNSON LORIN K

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.